Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

Powerbridge Technologies Co Ltd

VEON

Check these three penny stocks out for your watchlist right now The post Top Penny Stocks to Buy Now? 3 to Watch in July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Buy Now? 3 to Watch in July

Kaspien Holdings Inc.

Windtree Therapeutics

Can these penny stocks climb this week? The post Check These Penny Stocks For Your Watchlist This Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These Penny Stocks For Your Watchlist This Week

iBio

China Rapid Finance

Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy in Mid-June 2022?

Hot Penny Stocks to Buy in Mid-June 2022? 3 to Watch

Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-FHAB) and a commercially available anti-PD1 antibody Combination of SON-1010 with anti-PD1 increased survival rate These data will guide future combination study designs with SON-1010 and checkpoint inhibitors PRINCETON, NJ / ACCESSWIRE / June 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today announced data from a preclinical combination study of SON-1010 with a commercially available anti-PD1 compound. These results suggest that dosing of SON-1010 (IL12- FHAB) in combination with anti-PD1 demonstrated strong efficacy in the B16F10 mouse melanoma model, historically known as an immunologically insensitive model to anti-PD1.

Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition

PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today announced that the Company's 2022 Annual Meeting of Stockholders, on June 2, 2022 at 9:00 a.m. Eastern Time, was convened and adjourned, without any business being conducted, due to lack of the required quorum.

Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum

IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors SON-080 on track to begin clinical studies by mid-2022 Preclinical data for SON-1010, SON-1210, and SON-1410 presented at the 2022 AACR Annual Meeting Preclinical development of additional FHAB pipeline assets progressing forward PRINCETON, NJ / ACCESSWIRE / May 10, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three and six months ended March 31, 2022 and provided a business update. "We are excited to have initiated the first clinical trial with our lead Fully Human Albumin Binding pipeline asset, SON-1010," said Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update

Camber Energy

Imperial Petroleum

Can these penny stocks continue to climb this month? The post Trending Penny Stocks to Buy This Month?

Trending Penny Stocks to Buy This Month? 3 to Watch in April

Artelo Biosciences Inc

Cybin

Meten Holding Group Ltd.

ProQR Therapeutics

Statera Biopharma Inc

Exela Technologies

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today

PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has been initiated in a Phase 1 clinical trial of SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors. SON-1010 is a proprietary version of human Interleukin 12 (IL-12), configured using Sonnet's Fully Human Albumin Binding (FHAB™) platform.

Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors

PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from preclinical studies of the company's proprietary Fully-Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022, April 8-13, in New Orleans, Louisiana. "We are excited about these data that support tumor growth reduction following administration of both SON-1210 and SON-1410 in a B16-F10 melanoma model in mice," said John Cini, Ph.D.

Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting

The FDA has signed off Sonnet BioTherapeutics Holdings Inc's (NASDAQ: SONN) Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) technology.  Sonnet will.

Sonnet Shares Surge As FDA Clears Its First Human Trial For Solid Tumor Candidate

Didi Global

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for March 16th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 16th, 2022

Represents Sonnet's first IND cleared Phase 1 trial initiation expected in 2Q22 PRINCETON, NJ / ACCESSWIRE / March 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB™) technology. This will allow Sonnet to initiate its First-in-Human Phase 1 trial in adult oncology patients in the second quarter of 2022.

Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors

PRINCETON, NJ / ACCESSWIRE / February 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from preclinical studies of the company's proprietary Fully Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, to be held April 8-13, in New Orleans, Louisiana. Details of the abstract and poster presentation are as follows: Title: An innovative human platform for targeted delivery of bispecific interleukins to tumors Abstract Number: 4229 Session: Immunology Presentation Type: Poster Session Date and Time: Wednesday April 13, 2022; 9:00 AM - 12:30 PM EDT Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38 Poster Board Number: 9 About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action.

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting

The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) fell by 4.57% in the most recent trading session. This is why it happened.

Sonnet BioTherapeutics (SONN) Stock: Why The Price Fell

SON-1010 and SON-080 on track to initiate clinical studies during the second quarter of 2022 Completed R&D manufacturing for SON-1210 non-GLP toxicity study in non-human primates, with study initiation planned for the first half of 2022 Continue to advance preclinical development of FHAB pipeline PRINCETON, NJ / ACCESSWIRE / February 8, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended December 31, 2021 and provided a business update. "Throughout the quarter, we've continued to advance towards the clinic with our proprietary Fully Human Albumin Binding (FHAB) pipeline assets, and our partnered product, SON-080," said Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update

PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30th, 2021 and provided a business update. Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update

Ault Global Holdings

Seanergy Maritime Hlds

With October off to a great start for penny stocks, which small-caps are you watching? The post Top Penny Stocks to Buy This Week?

Top Penny Stocks to Buy This Week? 3 You Need to Watch

Sesen Bio Inc.

Check these three penny stocks out for your September watchlist The post Penny Stocks That Will Explode? Check These 3 Out For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks That Will Explode? Check These 3 Out For Your List

The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 20% pre-market. This is why it happened.

SONN Stock: Why It Significantly Increased Today

HUMBL

Histogen

Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now?

Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September

​​​​​Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock is soaring during premarket in reaction to the selection of SON-1410 as a development candidate for melanoma and renal cancers. SON-1410 represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the Company's Fully Human Albumin Binding (FHAB) platform.

See Why Sonnet BioTherapeutics Stock Is Skyrocketing In Premarket Tuesday

The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 60% pre-market. This is why it happened.

SONN Stock: Over 60% Increase Pre-Market Explanation

SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs Selection of the asset was performed with input from Sonnet's Scientific Advisory Board An IND submission for SON-1410 is anticipated during the second half of 2022 PRINCETON, NJ / ACCESSWIRE / August 30, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has selected a novel development candidate after completing comparative studies in a mouse melanoma model. The candidate represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the company's Fully Human Albumin Binding (FHAB) platform.

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)

Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) priced the underwritten public offering of 35.3 million shares (including pre-funded warrants) and warrants to purchase up to 35.3 million shares.  Each share of common stock (or pre-funded warrant) has a combined price of $0.85, raising approximately $30.0 million gross proceeds.

Sonnet BioTherapeutics Stock Slumps After $30M Equity Raise

News for Sonnet BioTherapeutics Stock (SONN)